AR053326A1 - 4 - feniltetrahidroisoquinolinas sustituidas, su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por la activacion de nhe y composicion farmaceutica que las comprende. - Google Patents
4 - feniltetrahidroisoquinolinas sustituidas, su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por la activacion de nhe y composicion farmaceutica que las comprende.Info
- Publication number
- AR053326A1 AR053326A1 ARP060100092A ARP060100092A AR053326A1 AR 053326 A1 AR053326 A1 AR 053326A1 AR P060100092 A ARP060100092 A AR P060100092A AR P060100092 A ARP060100092 A AR P060100092A AR 053326 A1 AR053326 A1 AR 053326A1
- Authority
- AR
- Argentina
- Prior art keywords
- carbon atoms
- hydrogen
- cycloalkyl
- alkyl
- zero
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 230000004913 activation Effects 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 230000001404 mediated effect Effects 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 11
- 239000001257 hydrogen Substances 0.000 abstract 9
- 229910052739 hydrogen Inorganic materials 0.000 abstract 9
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 9
- 125000000217 alkyl group Chemical group 0.000 abstract 6
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 4
- 239000001301 oxygen Substances 0.000 abstract 4
- 229910052760 oxygen Inorganic materials 0.000 abstract 4
- 208000035475 disorder Diseases 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 206010041235 Snoring Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 208000020832 chronic kidney disease Diseases 0.000 abstract 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 238000002483 medication Methods 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000002859 sleep apnea Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/18—Aralkyl radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Los medicamentos que comprenden compuestos de este tipo son utiles en la prevencion o el tratamiento de diversos trastornos. Por ejemplo, los compuestos se pueden utilizar, inter alia, en el evento de trastornos renales, tales como insuficiencia renal aguada o cronica, en el evento de trastornos de la funcion biliar y en el evento de trastornos respiratorios tales como ronquidos o apneas del sueno. Se proveen también composiciones farmacéuticas que contienen a éstos compuestos como principio activo. Reivindicacion 1: Un compuesto de la formula (1) en donde R1, R2, R3 y R4 son cada uno, de manera independiente, hidrogeno, F, Cl, Br, I, CN, NO2 o R11-(CmH2m)-An-; m es cero, 1, 2, 3, o 4; n es cero o 1; R11 es hidrogeno, metilo o CpF2p+1; A es oxígeno, NH, N(CH3) o S(O)q; p es 1, 2 o 3; q es cero,1 o 2; R5 es hidrogeno, alquilo con 1, 2, 3, 4, 5 o 6 átomos de cicloalquilo con 3, 4, 5 o 6 átomos de carbono; R6 es hidrogeno, OH, F, CF3, alquilo con 1, 2, 3 o 4 átomos de carbono o cicloalquilo con 3,4 5 o 6 átomos de carbono; R7 y R8 son cada uno, de manera independiente, hidrogeno F, Cl, Br, CN, CO2R12, NR13R14 o R16-(CmmH2mm)-Bnn-; R12 es hidrogeno, alquilo con 1, 2, 3 o 4 átomos de carbono, cicloalquilo con 3, 4, 5 0 6 átomos de carbono; R13 y R14 son cada uno, de manera independiente, hidrogeno, alquilo con 1, 2, 3 o 4 átomos de carbono o cicloalquilo con 3, 4, 5 o 6 átomos de carbono; R13 y R14 con el átomo de nitrogeno al que están unidos forman un anillo de 4, 5, 6 o 7 miembros en donde un grupo CH2 puede estar reemplazado por NR15, S u oxígeno; R15 es hidrogeno, alquilo con 1, 2, 3 o 4 átomos de carbono o cicloalquilo con 3, 4, 5 o 6 átomos de carbono; mm es cero, 1, 2, 3 o 4; nn es cero o 1; R16 es oxígeno o S(O)qq; pp es 1, 2 o 3; qq es cero, 1 o 2; W es CrH3r o CsJ2S-2; en donde cada uno o varios grupos CH2 en CrH2r y CsH2s-2 pueden estar reemplazados por NR17, oxígeno o S; R17 es hidrogeno, alquilo con 1, 2, 3 o 4 átomos de carbono o cicloalquilo con 3,4, 5 o 6 átomos de carbono; r es 1, 2, 3, 4, 5, 6, 7 u 8; s es 2, 3, 4,5,6,7 u 8; x es -C(O)-o -S(O)2-; Z es -C(O)- o un enlace; y también sus sales trifuoroacetatos farmacéuticamente aceptables.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102005001411A DE102005001411A1 (de) | 2005-01-12 | 2005-01-12 | Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR053326A1 true AR053326A1 (es) | 2007-05-02 |
Family
ID=36121409
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060100092A AR053326A1 (es) | 2005-01-12 | 2006-01-10 | 4 - feniltetrahidroisoquinolinas sustituidas, su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por la activacion de nhe y composicion farmaceutica que las comprende. |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US7868003B2 (es) |
| EP (1) | EP1838315B1 (es) |
| JP (1) | JP2008526906A (es) |
| KR (1) | KR20070094916A (es) |
| CN (1) | CN101184488A (es) |
| AR (1) | AR053326A1 (es) |
| AU (1) | AU2005324833A1 (es) |
| BR (1) | BRPI0519854A2 (es) |
| CA (1) | CA2594419A1 (es) |
| CR (1) | CR9191A (es) |
| DE (1) | DE102005001411A1 (es) |
| DK (1) | DK1838315T3 (es) |
| DO (1) | DOP2006000011A (es) |
| ES (1) | ES2470980T3 (es) |
| GT (1) | GT200600017A (es) |
| IL (1) | IL184314A0 (es) |
| MA (1) | MA29227B1 (es) |
| MX (1) | MX2007008269A (es) |
| MY (1) | MY142493A (es) |
| NI (1) | NI200700162A (es) |
| NO (1) | NO20074084L (es) |
| NZ (1) | NZ556080A (es) |
| PA (1) | PA8659501A1 (es) |
| PT (1) | PT1838315E (es) |
| RU (1) | RU2398766C2 (es) |
| TN (1) | TNSN07263A1 (es) |
| TW (1) | TW200637842A (es) |
| UA (1) | UA88941C2 (es) |
| UY (1) | UY29333A1 (es) |
| WO (1) | WO2006074813A1 (es) |
| ZA (1) | ZA200704728B (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0918502A2 (pt) | 2008-09-02 | 2015-12-01 | Sanofi Aventis | aminoindanos substituídos e análogos dos mesmos, e o uso farmacêutico dos mesmos |
| SI2384318T1 (en) * | 2008-12-31 | 2018-03-30 | Ardelyx, Inc. | MEASURES AND PROCEDURES FOR THE INHIBITION OF ANTIPORT INHIBITED BY NHE IN THE TREATMENT OF DISEASES RELATED TO STRENGTH OF FLAMMABILITY OR TRADEMARITY WITH SOLO, AND THE EMISSION OF GASTROINTESTINAL TREATMENT |
| US10543207B2 (en) * | 2008-12-31 | 2020-01-28 | Ardelyx, Inc. | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
| US20120088737A2 (en) * | 2009-10-02 | 2012-04-12 | Ajinomoto Co., Inc | Novel acyl guanidine derivatives |
| BR112012015868A2 (pt) * | 2009-12-11 | 2017-06-20 | Autifony Therapeutics Ltd | derivados de imidazolidinadiona |
| US20130011480A1 (en) * | 2011-05-05 | 2013-01-10 | Rosenberg Mark A | Cytotoxic therapy by proton flux modulation |
| MX382203B (es) | 2013-04-12 | 2025-03-11 | Ardelyx Inc | Compuestos de union a nhe3 (intercambiador de sodio-hidrogeno 3) y metodos para inhibir transporte de fosfato. |
| KR102386666B1 (ko) * | 2014-07-25 | 2022-04-15 | 다이쇼 세이야꾸 가부시끼가이샤 | 헤테로아릴로 치환된 페닐테트라히드로이소퀴놀린 화합물 |
| JP6903923B2 (ja) * | 2016-01-22 | 2021-07-14 | 大正製薬株式会社 | ヘテロアリールで置換されたフェニルテトラヒドロイソキノリン化合物を有効成分として含有する医薬 |
| UA126283C2 (uk) | 2017-01-09 | 2022-09-14 | Арделікс, Інк. | Сполуки, придатні для лікування розладів шлунково-кишкового тракту |
| JP2020505333A (ja) | 2017-01-09 | 2020-02-20 | アルデリックス， インコーポレイテッド | Ｎｈｅ媒介性アンチポートの阻害薬 |
| CN114716458A (zh) * | 2021-01-04 | 2022-07-08 | 上海济煜医药科技有限公司 | 四氢异喹啉类化合物 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19633966A1 (de) | 1996-08-22 | 1998-02-26 | Hoechst Ag | Phenylsubstituierte Alkenylcarbonsäure-guanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| DE19945302A1 (de) | 1999-09-22 | 2001-03-29 | Merck Patent Gmbh | Biphenylderivate als NHE-3-Inhibitoren |
| WO2001032625A1 (en) * | 1999-11-03 | 2001-05-10 | Du Pont Pharmaceuticals Company | Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin |
| KR20080065707A (ko) | 1999-11-03 | 2008-07-14 | 에이엠알 테크놀로지, 인크. | 4-페닐-치환 테트라히드로이소퀴놀린, 및 노르에피네프린과도파민과 세로토닌의 재흡수를 차단하기 위한 이의 용도 |
| DE19960204A1 (de) | 1999-12-14 | 2001-06-28 | Aventis Pharma Gmbh | Substituierte Norlbornylamino-Derivate, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| DE10015248A1 (de) | 2000-03-28 | 2001-10-04 | Merck Patent Gmbh | Bisamidino-Verbindungen als NHE-3 Inhibitoren |
| DE10019062A1 (de) | 2000-04-18 | 2001-10-25 | Merck Patent Gmbh | 2-Guanidino-4-aryl-chinazoline als NHE-3 Inhibitoren |
| ATE425968T1 (de) * | 2001-12-05 | 2009-04-15 | Sanofi Aventis Deutschland | Substituierte 4-phenyltetrahydroisochinoline, verfahren zu ihrer herstellung, ihre verwendung als medikament, sowie sie enthaltendes medikament |
| DE10163914A1 (de) | 2001-12-22 | 2003-07-03 | Aventis Pharma Gmbh | Substituierte 4-Phenyltetrahydroisochinolinium-Salze, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament |
| DE10312963A1 (de) * | 2003-03-24 | 2004-10-07 | Aventis Pharma Deutschland Gmbh | Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament |
-
2005
- 2005-01-12 DE DE102005001411A patent/DE102005001411A1/de not_active Withdrawn
- 2005-12-30 DK DK05823573.0T patent/DK1838315T3/da active
- 2005-12-30 ES ES05823573.0T patent/ES2470980T3/es not_active Expired - Lifetime
- 2005-12-30 CA CA002594419A patent/CA2594419A1/en not_active Abandoned
- 2005-12-30 NZ NZ556080A patent/NZ556080A/en not_active IP Right Cessation
- 2005-12-30 UA UAA200709180A patent/UA88941C2/ru unknown
- 2005-12-30 KR KR1020077015974A patent/KR20070094916A/ko not_active Withdrawn
- 2005-12-30 WO PCT/EP2005/014127 patent/WO2006074813A1/de not_active Ceased
- 2005-12-30 CN CNA2005800465296A patent/CN101184488A/zh active Pending
- 2005-12-30 MX MX2007008269A patent/MX2007008269A/es active IP Right Grant
- 2005-12-30 EP EP05823573.0A patent/EP1838315B1/de not_active Expired - Lifetime
- 2005-12-30 BR BRPI0519854-2A patent/BRPI0519854A2/pt not_active IP Right Cessation
- 2005-12-30 RU RU2007130706/04A patent/RU2398766C2/ru not_active IP Right Cessation
- 2005-12-30 AU AU2005324833A patent/AU2005324833A1/en not_active Abandoned
- 2005-12-30 PT PT58235730T patent/PT1838315E/pt unknown
- 2005-12-30 JP JP2007550712A patent/JP2008526906A/ja not_active Abandoned
-
2006
- 2006-01-10 TW TW095100824A patent/TW200637842A/zh unknown
- 2006-01-10 AR ARP060100092A patent/AR053326A1/es not_active Application Discontinuation
- 2006-01-11 PA PA20068659501A patent/PA8659501A1/es unknown
- 2006-01-11 GT GT200600017A patent/GT200600017A/es unknown
- 2006-01-11 MY MYPI20060103A patent/MY142493A/en unknown
- 2006-01-12 DO DO2006000011A patent/DOP2006000011A/es unknown
- 2006-01-12 UY UY29333A patent/UY29333A1/es unknown
-
2007
- 2007-06-14 ZA ZA200704728A patent/ZA200704728B/en unknown
- 2007-06-19 CR CR9191A patent/CR9191A/es not_active Application Discontinuation
- 2007-06-21 NI NI200700162A patent/NI200700162A/es unknown
- 2007-07-01 IL IL184314A patent/IL184314A0/en unknown
- 2007-07-06 MA MA30050A patent/MA29227B1/fr unknown
- 2007-07-11 TN TNP2007000263A patent/TNSN07263A1/en unknown
- 2007-07-11 US US11/776,041 patent/US7868003B2/en not_active Expired - Fee Related
- 2007-08-07 NO NO20074084A patent/NO20074084L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NZ556080A (en) | 2009-08-28 |
| EP1838315B1 (de) | 2014-03-12 |
| UY29333A1 (es) | 2006-08-31 |
| MY142493A (en) | 2010-11-30 |
| NO20074084L (no) | 2007-09-28 |
| UA88941C2 (ru) | 2009-12-10 |
| ES2470980T3 (es) | 2014-06-24 |
| JP2008526906A (ja) | 2008-07-24 |
| AU2005324833A1 (en) | 2006-07-20 |
| RU2398766C2 (ru) | 2010-09-10 |
| DE102005001411A1 (de) | 2006-07-27 |
| DK1838315T3 (da) | 2014-06-16 |
| CN101184488A (zh) | 2008-05-21 |
| RU2007130706A (ru) | 2009-02-20 |
| EP1838315A1 (de) | 2007-10-03 |
| WO2006074813A1 (de) | 2006-07-20 |
| US7868003B2 (en) | 2011-01-11 |
| NI200700162A (es) | 2008-04-21 |
| ZA200704728B (en) | 2008-07-30 |
| CA2594419A1 (en) | 2006-07-20 |
| BRPI0519854A2 (pt) | 2009-03-24 |
| MX2007008269A (es) | 2008-01-16 |
| IL184314A0 (en) | 2007-10-31 |
| TNSN07263A1 (en) | 2008-12-31 |
| TW200637842A (en) | 2006-11-01 |
| MA29227B1 (fr) | 2008-02-01 |
| KR20070094916A (ko) | 2007-09-27 |
| GT200600017A (es) | 2006-08-28 |
| PT1838315E (pt) | 2014-05-26 |
| CR9191A (es) | 2007-10-04 |
| PA8659501A1 (es) | 2006-09-08 |
| DOP2006000011A (es) | 2006-07-15 |
| US20080058328A1 (en) | 2008-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR056519A1 (es) | 4-feniltetrahidroisoquinolinas sustituidas, composiciones farmaceuticas que las contienen y usos terapeuticos en trastornos renales, respiratorios y otros | |
| AR082152A1 (es) | Derivados de n-(metilsulfonil)benzamida, composiciones farmaceuticas que los comprenden y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de nav1.7 | |
| AR053326A1 (es) | 4 - feniltetrahidroisoquinolinas sustituidas, su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por la activacion de nhe y composicion farmaceutica que las comprende. | |
| TWI262917B (en) | 2-Furancarboxylic hydrazides and pharmaceutical compositions containing the same | |
| AR066460A2 (es) | Compuestos derivados de fenil-piperazina, fenil-piperidina y fenil-tetrahidropiridina como inhibidores de la reabsorcion de la serotonina, una composicion farmaceutica y utilizacion de los mismos para la preparacion de medicamentos | |
| AR067051A1 (es) | Indazoles sustituidos, su preparacion y su utilizacion terapeutica | |
| AR063602A1 (es) | Derivados de espiroindolinona, formulaciones farmaceuticas que los contienen y su uso en la obtencion de un medicamento para el tratamiento de trastornos oncologicos. | |
| NO20073325L (no) | Nye naftalenforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem | |
| CL2004000917A1 (es) | Compuestos derivados de tiazol; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de enfermedades mediadas por 3-cinasa de dosfatidilnositol tal como enfermedades respiratorias, alergias, artritis reumatoide, osteoa | |
| RU2009125578A (ru) | Новые замещенные диазаспиропиридиноновые производные для применения в лечении мсн-1-опосредованных заболеваний | |
| AR063804A1 (es) | Compuestos de azoniabiciclo[2.2.2]octano | |
| CY1116183T1 (el) | Πιπεραζινοδιονες ως ανταγωνιστες υποδοχεα οξυτοκινης | |
| AR071055A1 (es) | Compuestos espiro, composiciones farmaceuticas y medicamentos que los comprenden, agente promotor de la secrecion de insulina y usos para la preparacion de medicamentos y composiciones farmaceuticas | |
| AR067475A1 (es) | Antagonistas no basico s del receptor de la hormona concentradora de melanina 1 | |
| AR082153A1 (es) | N-sulfonilbenzamidas utiles como inhibidor del canal de sodio | |
| AR069796A1 (es) | Derivados de bencimidazol, sustituido por carboxilo o por hidroxilo, proceso para prepararlos y composiciones farmaceuticas que los contienen | |
| AR060536A1 (es) | Agonista del receptor de glucocorticoides y composiciones farmaceuticas | |
| AR063028A1 (es) | Derivados heterociclicos de piridin-2-carboxamida activadores de glucoquinasas, utiles para el tratamiento de diabetes y obesidad y composiciones farmaceuticas que los contienen. | |
| AR064253A1 (es) | Compuestos de biciclocarboxiamida sustituidos composiciones farmaceuticas y una combinacion que los incluye y su uso en fabaricacion de un medicamento para el tratamiento de enfermedades mediadas por la actividad del receptor vr1 | |
| AR074583A1 (es) | 4-azetidinil-1-heteroaril-ciclohexanol antagonistas del ccr2 | |
| AR043741A1 (es) | 4-feniltetrahidroisoquinoleinas sustituidas, su uso como un medicamento, y el medicamento que las comprende | |
| AR076310A1 (es) | 4-azetidinil-1-heteroaril ciclohexanos sustituidos antagonistas de ccr2,composiciones farmaceuticas que los contienen, proceso para prepararlos y uso de los mismos en el tratamiento de diabetes,obesidad y otras enfermedades. | |
| AR118983A1 (es) | Antagonistas cíclicos del receptor b2 de bradiquinina | |
| AR054863A1 (es) | DERIVADOS DE 1H-PIRROLO[3, 4-C]PIRAZOL, UN PROCESO PARA SU PREPARACION, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN Y SU USO EN LA FABRICACION DE UN MEDICAMENTO PARA EL TRATAMIENTO O PROFILAXIS DE ENFERMEDADES ASOCIADAS CON EL FACTOR DE COAGULACIoN XA | |
| AR071721A1 (es) | Derivados de piridil-prolinamida, composiciones farmaceuticas que los contienen y su uso para el tratamiento de ansiedad, depresion y trastornos del sueno. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |